Valeant Pharmaceuticals Intl Inc. Acquired Salix Pharmaceuticals Ltd.:Now What?

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) has finished buying another company. Could a $2 billion product be the reason to buy this stock?

| More on:
The Motley Fool

It was announced on Wednesday that Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) had completed its acquisition of Salix Pharmaceuticals Ltd. for US$10.96 billion. This ends the drama that included another company that tried to outbid Valeant, only to be bested by the acquiring juggernaut.

But now the question stands: What should investors do with Valeant stock now that this acquisition is done?

It depends on your level of risk because Valeant is a really risky bet right now. To begin with, the company has over $20 billion in debt, which is a significant chunk of the company’s overall market cap. Furthermore, there’s little doubt in my mind that Valeant might try to acquire another company, which will force it to bring on even more debt.

However, due to where interest rates are today and how easy money is flowing into these companies, it doesn’t seem like the worst situation for Valeant to take on debt when the times are good. If you can handle that risk of high debt, then Valeant could pay off in the long run because this acquisition could bear some significant fruit for the combined entity.

First and foremost, the cost savings of combining the two companies is expected to be around US$500 million within six months. This is coming from cuts in administration, sales, marketing, and research and development.

There is also the fact that moving Salix Pharmaceuticals from its headquarters in Raleigh, NC to Toronto, ON, the tax rate will drop severely. Paying only 5% on taxes will have a significant impact on the bottom line for Valeant.

However, the real reason this acquisition went down was because of Xifaxan 550. This is an antibiotic that is meant to treat diarrhea caused by E. coli. By May 27 we will know whether the FDA is going to approve the data from a new phase III study. If it does, this acquisition makes perfect sense. According to EvaluatePharma, Xifaxan could account for nearly US$2 billion a year in sales by 2020. That’s 24% of the total expected 2020 sales for the combined entity. And what’s particularly good is the patent for Xifaxan doesn’t expire until June 2024, so there is a long runway for Valeant to profit on it.

Should you buy?

If times were different, I would say avoid Valeant because it has a lot of debt. But the way the economy is right now with money lending, it doesn’t seem to be too much of a problem. If the debt concerns you, then you should avoid it.

However, if you want to follow hedge fund managers like Bill Ackman, buying Valeant isn’t a bad idea. However, I would wait to see if the price the stock is trading at now is its new low, or if it will break the support and fall back to pre-February numbers. Should it stay in the $240s, we might have a new price point for entry.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Jacob Donnelly has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

Bank sign on traditional europe building facade
Bank Stocks

Are Canadian Bank Stocks Still Undervalued?

Bank stock are moving higher. Is it time to buy or wait?

Read more »

You Should Know This
Stocks for Beginners

5 Things to Know About Cargojet Stock in November 2022

Cargojet (TSX:CJT) stock should continue to see massive growth in the near and long term, thanks to long-term agreements and…

Read more »

Double exposure of a businessman and stairs - Business Success Concept
Dividend Stocks

Better Buy: BCE Stock or Enbridge?

BCE and Enbridge pay growing dividends with high yields. Is one more attractive today?

Read more »


TFSA: 3 TSX Stocks to Buy With the New $6,500 Room Limit

Canadians who are eager to utilize the new $6,500 room limit in 2023 should look to TSX stocks like Aritzia…

Read more »

Financial technology concept.

The Smartest Stocks to Buy With $20 Right Now and Hold Forever

Given the favourable market conditions and their growth initiatives, these three under-$20 stocks offer excellent buying opportunities for long-term investors.

Read more »

Silver coins fall into a piggy bank.
Dividend Stocks

2 Unstoppable Dividend Stocks to Load Up in Your TFSA

These two dividend stocks provide long-term passive income that comes out every month, thanks to lease agreements lasting over a…

Read more »

Doctor talking to a patient in the corridor of a hospital.
Tech Stocks

3 Healthcare Stocks to Buy for Long-Term Passive Income

Healthcare stocks provide exposure to an essential service sector. They are also the best for passive income in the short…

Read more »

potted green plant grows up in arrow shape

4 TSX Growth Stocks to Buy and Hold Forever

Here's why TSX growth stocks, and these four stocks specifically, are some of the best investments you can buy in…

Read more »